MedTrace Logo

Almitrine in COVID-19 Patients With ARDS Treated by HFNO

NCT05216575 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2025-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of Almitrine administration on oxygenation in COVID-19 patients with acute respiratory distress syndrome treated by high-flow nasal canula oxygen therapy as first-line ventilatory support.

Conditions

  • ARDS
  • Hypoxemia

Interventions

DRUG

Administration of Almitrine

Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05216575 on ClinicalTrials.gov